Citation: Joseph Inungu, Kechi Iheduru-Anderson, Ossam J Odio. Recurrent Ebolavirus disease in the Democratic Republic of Congo: update and challenges[J]. AIMS Public Health, 2019, 6(4): 502-513. doi: 10.3934/publichealth.2019.4.502
[1] | Marte K.R. Kjøllesdal, Gerd Holmboe-Ottesen . Dietary Patterns and Birth Weight—a Review. AIMS Public Health, 2014, 1(4): 211-225. doi: 10.3934/Publichealth.2014.4.211 |
[2] | Carla Gonçalves, Helena Moreira, Ricardo Santos . Systematic review of mediterranean diet interventions in menopausal women. AIMS Public Health, 2024, 11(1): 110-129. doi: 10.3934/publichealth.2024005 |
[3] | Hanan E. Badr, Travis Saunders, Omar Bayoumy, Angelie Carter, Laura Reyes Castillo, Marilyn Barrett . Reversal for metabolic syndrome criteria following the CHANGE program: What are the driving forces? Results from an intervention community-based study. AIMS Public Health, 2025, 12(1): 162-184. doi: 10.3934/publichealth.2025011 |
[4] | Truong Tuyet Mai, Tran Thu Trang, Tran Thi Hai . Effectiveness of germinated brown rice on metabolic syndrome: A randomized control trial in Vietnam. AIMS Public Health, 2020, 7(1): 33-43. doi: 10.3934/publichealth.2020005 |
[5] | Jürgen Vormann . Magnesium: Nutrition and Homoeostasis. AIMS Public Health, 2016, 3(2): 329-340. doi: 10.3934/publichealth.2016.2.329 |
[6] | Yu Li, Zhehui Luo, Claudia Holzman, Hui Liu, Claire E. Margerison . Paternal race/ethnicity and risk of adverse birth outcomes in the United States, 1989–2013. AIMS Public Health, 2018, 5(3): 312-323. doi: 10.3934/publichealth.2018.3.312 |
[7] | Jennifer L Lemacks, Laurie S Abbott, Cali Navarro, Stephanie McCoy, Tammy Greer, Sermin Aras, Michael B Madson, Jacqueline Reese-Smith, Chelsey Lawrick, June Gipson, Byron K Buck, Marcus Johnson . Passive recruitment reach of a lifestyle management program to address obesity in the deep south during the COVID-19 pandemic. AIMS Public Health, 2023, 10(1): 116-128. doi: 10.3934/publichealth.2023010 |
[8] | Trong Hung Nguyen, Thi Hang Nga Nguyen, Hung Le Xuan, Phuong Thao Nguyen, Kim Cuong Nguyen, Tuyet Nhung Le Thi . Nutritional status and dietary intake before hospital admission of pulmonary tuberculosis patients. AIMS Public Health, 2023, 10(2): 443-455. doi: 10.3934/publichealth.2023031 |
[9] | Ragnar Rylander . Treatment with Magnesium in Pregnancy. AIMS Public Health, 2015, 2(4): 804-809. doi: 10.3934/publichealth.2015.4.804 |
[10] | John P. Elliott, John C. Morrison, James A. Bofill . Risks and Benefits of Magnesium Sulfate Tocolysis in Preterm Labor (PTL). AIMS Public Health, 2016, 3(2): 348-356. doi: 10.3934/publichealth.2016.2.348 |
Maternal malnutrition is a well-known causal factor for intrauterine fetal growth retardation, both in humans and animals. Several studies have shown that small birth size and indices in poor fetal growth are associated with the development of metabolic syndrome in adulthood, such as insulin resistance, type 2 diabetes, hypertension, dyslipidemia and coronary heart disease [1,2,3]. Studies have indicated that exposure to adverse environmental influences during critical periods of development may cause persistent changes in organ structure and function and later lead to impaired glucose tolerance and type 2 diabetes, a phenomenon known as “programming” [2,3,4]. As birth size is mainly determined by non-genetic factors, these findings have led to the “developmental origins of health and disease (DOHaD)” hypothesis, whereby abnormal fetal growth as a result of fetal adaptation adverse intrauterine conditions may program lifelong physiological changes [5,6,7,8].
In spontaneous pregnancies smaller increases of thyroid stimulating hormone levels are related to higher magnesium (Mg) levels [9]. It has been reported that maternal intake of Mg is associated not only with fetal development, but also with the health of the newborn [10]. A daily intake of Mg during pregnancyis recommended as 1.40 mmol/day [11]. In India 44% of pregnant women consume less Mg in their diet [12]. Another study has demonstrated that pregnant mothers who drink water with a high Mg content lower their risk of having very low birth weight infants (less than 1,500 g of birth weight) [13].
The role of Mg as a cofactor for enzymes in carbohydrate metabolism also involves insulin activity [14]. Mg deficiency has been observed in cases of diabetes and vascular disease [15,16,17,18]. Lowere plasma Mg concentrations (less than 0.83mmol/L) was associated with insulin resistance in steady-state plasma insulin response to continuous glucose infusion [15]. The results from these experimental and epidemiological studies suggest that Mg levels and birth weight are key determinants of insulin resistance.
In this review, we propose that intrauterine Mg deficiency may later manifest as metabolic syndrome in adulthood, and discuss the association of Mg regulation with low birth weight and metabolic syndrome.
Small for gestational age (SGA)babies are those who are smaller in size than normal by gestational age and are commonly defined as having a birth weight below the 10th percentile by gestational age [19]. Mineral concentrations of meconium in SGA newborns and those of appropriate for gestational age (AGA) newborns of similar gestational age were compared to determine whether differences may provide clues of possible nutritional deficits of SGA infants. The concentration of minerals in meconium is known to be indicative of minerals used by the fetus and minerals supplied to the fetus by the mother [20]. In the less than 35-week subgroups, the SGA group had lower meconium iron and manganese concentrations than those of the AGA group. Among more than 36-week newborns, SGA infants had a higher copper concentration than AGA infants when adjusted for birth-rate. No differences were observed in zinc, calcium (Ca), Mg, or phosphorus concentrations. These results may reflect either a greater use of minerals or a decreased maternal supply [20].
The levels of total Ca, ionized Ca, and Mg are higher in fetal circulation than in maternal blood[21]. Copper and selenium share the same transport pathway in the placental membrane along a concentration gradient in the maternal-fetal direction, whereas active transport largely influences the transfer of Mg and iron [22]. In fact, evidence for the existence of an active transport mechanism for Mg in the placenta was suggested by using cultured trophoblast cells, i.e. a functional Na+/Mg2+ exchanger that functions to maintain low intracellular Mg [23]. The activity of this exchanger might be influenced by maternal plasma sodium concentration as experimental rats with acute maternal hyponatremia showed reduced maternal-fetal transfer of Mg via the placenta [24], while other pathways of Mg transport may also exist in the placenta. Recently, Yang H et al reported that magnesium/inorganic phosphorus channels expression is down-regulated in cases of preeclampsia and under hypoxia [25]. By the end of a normal pregnancy, the fetus is believed to have acquired approximately 28 g of calcium, 16 g of phosphorous, and 0.7 g of Mg, mostly during the third trimester, also the time when 80% of fetal accretion of Mg occurs [26]. Whereas mean levels of ionized Ca do not change during labor, the mean maternal serum levels of ionized Mg and total Mg fall at delivery, suggests the presence of homeostatic mechanisms in the fetus and placenta and indicating that free Mg in umbilical venous blood may enhance Mg transport to the fetus [27].
In mammals, the placenta is a highly developed organ which, along with nutrient exchange, has numerous other functions during the gestational period with maternal-fetal homeostasis dependant on a properly functioning placenta. Maternal Mg deficiency obviously affects the health of the fetus. However, some studies have not found a significant association between maternal trace elements and birth weight [28].
Ca and Mg are cofactors in the synthetic activity of a number of enzymes. A variety of hormones, cytokines and growth factors produced by fetal membranes and placenta can act locally on the myometrium [29]. It has been suggested that upregulation of multiple pathways involved in the production of nitric oxide (NO) is connected to the dilation of the uterine artery during pregnancy [30]. While the activity of constitutive NO synthase is dependent on Ca, the enzyme can also be inhibited by a reduction in the concentration of Mg [31]. In cases of preterm labor, the fetal membrane has a reduced permeability to Ca and Mg which could be an important factor in the activation of the myometrium in these cases [32].
Mg along with Ca and NO has an immediate effect on placental vascular flow. Reduced placental vascular flow is at least, in part, responsible for placental insufficiency and SGA (Figure 1).
A variety of hormones, cytokines and growth factors produced by fetal membranes and placenta can act on the myometrium. The ability of the uterine artery to dilate may be related to nitric oxide. Several candidate processes have been proposed to explain gestational programming, i.e. epigenetic modification of gene. (adapted from Takaya J, Yamato F, Kaneko K. (2006) Possible relationship between low birth weight and magnesium status: from the standpoint of “fetal origin” hypothesis. Magnes. Res. 20,63-9)IGF-1: insulin-like growth factor-1, iP: inorganic phosphorus, NO: Nitric oxide, Mg: magnesium, SGA: small for gestational age.
Human platelets are often used in studying cellular cation metabolism in various diseases [33] because they are readily available and are thought to share a number of features with vascular smooth muscle cells. Additionally, insulin receptors in platelets have similar characteristics to those of other cells [34].
We and other investigators have proposed that insulin action could be mediated by intracellular Mg ([Mg2+]i) in platelets [35,36]. In fact, Mg deficiency occurs in adult patients with diabetes mellitus and vascular diseases [16,17,18] and children with diabetes and obesity have been reported to have [Mg2+]i deficiency [35].
Together, this evidence shows that decreased [Mg2+]i might underlie the initial pathophysiologic events leading to insulin resistance and further tested whether the origin of [Mg2+]i deficiency may start from fetal life in SGA caused by genetic factors or intrauterine environment.
By using a fluorescent probe, mag-fura-2, we examined [Mg2+]i of platelets in the cord blood of infants with SGA and with AGA [36]. Mean [Mg2+]i, but not plasma Mg, was lower in the SGA than in the AGA group (284 ± 33 mmol/L vs 468 ± 132 mmol/L, p < 0.001). [Mg2+]I was significantly correlated with the birth weight (p < 0.001) and birth length (p < 0.001) (Figure 2,3).
As [Mg2+]i plays a promotive role in fetal growth, low [Mg2+]i may partly be responsible for SGA. In regard to fetal life, it has been postulated that nutritional and environmental factors during pregnancy, as well as hormonal factors such as insulin and IGF-1 [37] play important roles in addition to genetic predisposition.
The basal level of intracellular Mg2+ of cord blood platelets is significantly correlated with birth weight (p < 0.001, r = 0.61). ○, appropriate for gestational age (AGA); ●, small for gestational age(SGA) (adapted from Reference 36)
The basal level of intracellular Mg2+ of cord blood platelets is significantly correlated with birth length (p < 0.001, r = 0.48). ○, appropriate for gestational age (AGA); ●, small for gestational age(SGA). (adapted from Reference 39)
Adiponectin and IGF-1 were lower in SGA than in AGA groups, while plasminogen activator inhibitor (PAI)-1 and ghrelin were higher in SGA groups (Table 1). Quantitative insulin sensitivity check index (QUICKI) has an excellent linear correlation with the glucose clamp index of insulin sensitivity [38]. Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) and QUICKI are the most widely used indices for assessing insulin sensitivity. QUICKI was lower in SGA than in AGA groups (Table 1). Birth weight was correlated with cord plasma IGF-1 (p < 0.001), adiponectin(p < 0.001) and leptin (p < 0.005). [Mg2+]i, and adiponectin were correlated with QUICKI in all subjects (Fig4 )[39]. These results show that SGA individuals have the tendencies toward insulin resistance. [Mg2+]i was significantly associated with adiponectin (r = 0.246, p = 0.04), IGF-1(r = 0.272, p < 0.03), QUICKI (r = 0.592, p < 0.0001)(Figure 4). From these findings, [Mg2+]i as well as leptin and IGF-1 can be used to indicate the extent of fetal growth. Lower [Mg2+]i may be involved in the underlying processes that result in insulin resistance.
SGA | AGA | |||
(n = 20) | (n = 45) | |||
[Mg2+]i (μmol/L) | 284 ± 33*** | 468 ± 132 | ||
Plasma Mg(mmol/L) | 0.60 ± 0.03 | 0.61 ± 0.02 | ||
Adiponectin(μg/mL) | 11.4 ± 1.8** | 17.1 ± 1.0 | ||
IGF-1(ng/mL) | 14.3 ± 2.1** | 30.3 ± 2.2 | ||
Leptin(pg/mL) | 845 ± 215 | 1,260 ± 137 | ||
Ghrelin(fmol/mL) | 76.8 ± 11.0* | 53.7 ± 5.1 | ||
PAI-1(ng/mL) | 13.20 ± 2.52* | 7.97 ± 0.94 | ||
QUICKI | 0.35 ± 0.02*** | 0.41 ± 0.01 | ||
SGA: small for gestational age, AGA: appropriate for gestational age, [Mg2+]i: intracellular magnesium, PAI-1: plasminogen activator inhibitor-1, QUICKI: Quantitative insulin sensitivity check index. *p < 0.05, **p < 0.005, ***p < 0.0001 (adapted from Reference 39) |
In summary low [Mg2+]i, may influence the prenatal programming of insulin resistance, and may have lifelong effects on metabolic regulation characterized by insulin resistance.
The basal level of intracellular Mg2+ of cord blood platelets is significantly correlated with QUICKI (p < 0.001, r = 0.59). ○, appropriate for gestational age (AGA); ●, small for gestational age(SGA). (adapted from Reference 39)
The fetal origin hypothesis by Barker et al. [3,6,7] states that fetal undernutrition in middle to late gestation leads to disproportionate fetal growth programs and later metabolic diseases. Fetal programming is a phenomenon in which alterations in fetal growth and development in response to the prenatal environment have long-term or permanent effects. This theory was further established in the category of DOHaD [8]. The mechanisms connected with fetal programming include the direct effects on cell number, altered stem cell function, and the resetting of regulatory hormonal axes; hypothalamic-pituitary-adrenal axis [40,41] and growth hormone insulin-like growth factor axis [42]. One of the underlying mechanisms for the postulated early-life programming is epigenetics. Altered epigenetic regulation of genes in phenotype induction could possibly give rise to interventions that modify long-term disease risk associated with unbalanced nutrition in early life [43].
Although low birth weight and poor prenatal nutrition are strongly associated with metabolic syndrome in later life, postnatal catch-up growth was recently considered to also be a pivotal element associated with the development of various pathological conditions [44]. The concept of a sensitive or crucial period that whereby the fetus is susceptible to long-term changes in development and adverse outcomes later in life is an intriguing one and should be the focus of future studies.
(1) Fetal programming
Fetal programming is the phenomenon whereby alteration in fetal growth and development in response to the prenatal environment has long-term or permanent effects. The mechanisms involved are believed to have a direct effect on cell number, altered stem cell function and resetting of regulatory hormonal axes (Figure 5).
There are several candidates that may be involved in gestational programming: [i] a potential role for the hypothalamic-pituitary-adrenal axis has been suggested, as the mediators of the fetal response to nutrient stress, i.e. maternal low protein diet, were profoundly suppressed [45]; [ii] fetal programming of the growth hormone insulin-like growth factor axis also has been proposed to serve as a link between fetal growth and adult-onset disease [42].
(2) Thrifty phenotype hypothesis
The “thrifty phenotype hypothesis”, which postulates that fetal programming for adaptation to an adverse intrauterine environment results in lower insulin sensitivity in utero, is one of the hypotheses to explain the association between low birth weight and insulin resistance in later life [46].
Decreased [Mg2+]i in infants with SGA can be the initial pathophysiologic events of fetal programming. A recent animal study supported our data demonstrating that the maternal Mg restriction irreversibly increases body fat and induces insulin resistance in pups by 6 months of age [47].
(3) Epigenetic modification of gene expression
It is intriguing in clinical practice that the intrauterine environment can program adult disease susceptibility by altering the epigenetic state of the fetal genome, hence affecting the phenotype without changing the DNA sequence [48]. The changes in the intrauterine environment may ultimately lead to altered gene expression via alterations in DNA methylation and other epigenetic mechanisms, resulting in an increased susceptibility to chronic disease in adulthood [49].
Biological methylation reaction is dependent on dietary methyl donors and on cofactors. Mg acts as a cofactor for the binding of protein to its specific site in DNA by inducing conformational changes in the protein [50]. Mg also changes the conformation to a more helical structure which could provide specific geometrical constraints complementary to those of DNA helix.
Quantitative real-time PCR-based methylation analysis of three glucocorticoid related genes was performed from liver samples of offspring. In a rat model we found that a Mg-deficient diet in pregnant rats induces hypermethylation of specific CpG dinucleotides in the hepatic 11b-hydroxysteroid dehydrogenase-2 (Hsd11b2)promoter of infantile offspring [51]. These results show that nutrient constraint before birth induces persistent CpG-specific changes to the epigenetic regulation of the Hsd11b2promoter and that these changes are associated with altered mRNA expression. Venu et al. reported that fasting insulin and HOMA-IR underwent an increase in the offspring of Mg restricted dams at 6 months of age [47]. Maternal and postnatal Mg status is important in the long-term programming of body adiposity and insulin secretion in rat offspring [52].
In addition to the classical mechanisms of gene deletion or inactivation by point mutations, some genes can be functionally inactivated by methylation of cytosine residues in the promoter region without any alteration to their primary sequences. Epigenetic regulation of gene transcription provides a strong candidate mechanism for fetal programming. Inactivation of genes is an important event contributing to the development of metabolic diseases. Changes in Hsd11b2 probably contribute to marked increases in glucocorticoid hormone action in tissues and thereby potentiate the induction of insulin resistance in adult life.
Mg deficiency promotes apoptosis in cardiovascular cells, oxidative stress, and DNA damage [53]. Recently, Shah et al reported that Mg deficiency results in downregulation of telomerase and upregulation of transcription factores in rat cardiac and aortic smooth muscle cells [54].
Birth weight is only a crude index of early growth and does not indicate the success of a fetus in achieving its growth potential. [Mg2+]i may be a marker of early growth restriction, which may be of future diagnostic use as an early predictor of adult diseases. Low [Mg2+]i, which may represent the prenatal programming of insulin resistance, has lifelong effects on metabolic regulation. A biological interpretation of the association between birth size and risk of insulin-resistant diseases should emphasize the possible underlying roles of [Mg2+]i.
All authors declare no conflict of interest in this article.
[1] |
Wannier SR, Worden L, Hoff NA, et al. (2019) Estimating the impact of violent events on transmission in Ebola virus disease outbreak, Democratic Republic of the Congo, 2018–2019. Epidemics 28: 100353. doi: 10.1016/j.epidem.2019.100353
![]() |
[2] | National Academies of Sciences, Engineering, and Medicine (2016) The Ebola Epidemic in West Africa: Proceedings of a Workshop. National Academies Press. |
[3] |
Richardson JS, Dekker JD, Croyle MA, et al. (2010) Recent advances in Ebolavirus vaccine development. Hum Vaccines 6: 439–449. doi: 10.4161/hv.6.6.11097
![]() |
[4] |
Maxmen A (2019) Science under fire: Ebola researchers fight to test drugs and vaccines in a war zone. Nat 572: 16–17. doi: 10.1038/d41586-019-02258-4
![]() |
[5] | World Health Organization (2018) Notes for the record: consultation on Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) for Ebola virus disease (EVD). |
[6] | Ilunga Kalenga O, Moeti M, Sparrow A, et al. (2019) The ongoing Ebola Epidemic in the Democratic Republic of Congo, 2018–2019. N Engl J Med. |
[7] |
Kennedy SB, Bolay F, Kieh M, et al. (2017) Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia. N Engl J Med 377: 1438–1447. doi: 10.1056/NEJMoa1614067
![]() |
[8] |
Sullivan NJ, Sanchez A, Rollin PE, et al. (2000) Development of a preventive vaccine for Ebola virus infection in primates. Nat 408: 605. doi: 10.1038/35046108
![]() |
[9] |
Geisbert TW, Pushko P, Anderson K, et al. (2002) Evaluation in nonhuman primates of vaccines against Ebola virus. Emerging Infect Dis 8: 503. doi: 10.3201/eid0805.010284
![]() |
[10] | World Health Organization (2019) Preliminary results on the efficacy of rVSV-ZEBOV- GP Ebola vaccine using the ring vaccination strategy in the control of an Ebola outbreak in the Democratic Republic of the Congo: an example of integration of research into epidemic response. Geneva: Organ. |
[11] |
Baseler L, Chertow DS, Johnson KM, et al. (2017) The pathogenesis of Ebola virus disease. Annu Rev Pathol: Mech Dis 12: 387–418. doi: 10.1146/annurev-pathol-052016-100506
![]() |
[12] | World Health Organization (1978) Ebola haemorrhagic fever in Zaire, 1976. Report of an international commission. Bull World Health Organ 56: 271–293. |
[13] | Rojek AM, Salam A, Ragotte RJ, et al. (2019) A systematic review and meta-analysis of patient data from the west Africa (2013–16) Ebola virus disease epidemic. Clin Microbiol Infect. |
[14] | Benowitz I, Ackelsberg J, Balter SE, et al. (2014) Surveillance and preparedness for Ebola virus disease-New York City, 2014. MMWR Morbidity Mortal Wkly Rep 63: 934. |
[15] |
Yuan J, Zhang Y, Li J, et al. (2012) Serological evidence of Ebolavirus infection in bats, China. Virol J 9: 236. doi: 10.1186/1743-422X-9-236
![]() |
[16] | Formenty P, Hatz C, Le Guenno B, et al. (1999) Human infection due to Ebola virus subtype Cote d'Ivoire: clinical and biologic presentation. J Infect Dis 179 (Supplement 1): S48–S53. |
[17] |
Feldmann H (2014) Ebola-a growing threat? N Engl J Med 371: 1375–1378. doi: 10.1056/NEJMp1405314
![]() |
[18] |
Selvaraj SA, Lee KE, Harrell M, et al. (2018) Infection Rates and Risk Factors for Infection Among Health Workers During Ebola and Marburg Virus Outbreaks: A Systematic Review. J Infect Dis 218: S679–S689. doi: 10.1093/infdis/jiy435
![]() |
[19] |
Martínez MJ, Salim AM, Hurtado JC, et al. (2015) Ebola virus infection: overview and update on prevention and treatment. Infect Dis Ther 4: 365–390. doi: 10.1007/s40121-015-0079-5
![]() |
[20] |
Kaushik A, Tiwari S, Jayant RD, et al. (2016) Towards detection and diagnosis of Ebola virus disease at point-of-care. Biosens Bioelectron 75: 254–272. doi: 10.1016/j.bios.2015.08.040
![]() |
[21] |
Roddy P, Howard N, Van Kerkhove MD, et al. (2012) Clinical manifestations and case management of Ebola haemorrhagic fever caused by a newly identified virus strain, Bundibugyo, Uganda, 2007–2008. PloS One 7: e52986. doi: 10.1371/journal.pone.0052986
![]() |
[22] | Iwen PC, Smith PW, Hewlett AL, et al. (2015) Safety considerations in the laboratory testing of specimens suspected or known to contain Ebola virus. |
[23] | Yang M, Ke Y, Liu C, et al. (2015) Diagnosis of Ebola virus disease: progress and prospects. Infect Dis Transl Med 1: 73–79. |
[24] |
Saijo M, Niikura M, Morikawa S, et al. (2001) Immunofluorescence method for detection of Ebola virus immunoglobulin G, using HeLa cells which express recombinant nucleoprotein. J Clin Microbiol 39: 776–778. doi: 10.1128/JCM.39.2.776-778.2001
![]() |
[25] |
Li Y, Cu Y, Luo D (2005) Multiplexed detection of pathogen DNA with DNA-based fluorescence nanobarcodes. Nat Biotechnol 23: 885. doi: 10.1038/nbt1106
![]() |
[26] | Fenner F, Henderson DA, Arita I, et al. (1988) Smallpox and its eradication: World Health Organization Geneva. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2491071/pdf/bullwho00076-0026.pdf. |
[27] | World Health Organization (2014) Contact tracing during an outbreak of Ebola virus disease. |
[28] | World Health Organization (2015) The ring vaccination trial: a novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola. BMJ Br Med J 351: h3740. |
[29] | World Health Organization (2019) Ebola Virus Disease. Democratic Republic of the Congo External Situation Report 39. Available from: http://newsletters.afro.who.int/icfiles/1/46425/184054/6134450/97816cb57ede15249d4eb5b5/sit rep_evd_d%20rc_20190430-eng.pdf?ua=1,%20accessed%207%20May%202019. |
[30] | Kadanali A, Karagoz G (2015) An overview of Ebola virus disease. North Clin Istanbul 2: 81. |
[31] |
Marzi A, Robertson SJ, Haddock E, et al. (2015) VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Sci 349: 739–742. doi: 10.1126/science.aab3920
![]() |
[32] |
Marzi A, Engelmann F, Feldmann F, et al. (2013) Antibodies are necessary for rVSV/ZEBOV-GP–mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci 110: 1893–1898. doi: 10.1073/pnas.1209591110
![]() |
[33] |
Pavot V (2016) Ebola virus vaccines: Where do we stand? Clin Immunol 173: 44–49. doi: 10.1016/j.clim.2016.10.016
![]() |
[34] |
Geisbert TW, Feldmann H (2011) Recombinant vesicular stomatitis virus–based vaccines against Ebola and Marburg virus infections. J Infect Dis 204: S1075–S1081. doi: 10.1093/infdis/jir349
![]() |
[35] | Roberts A, Buonocore L, Price R, et al. (1999) Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol 73: 3723–3732. |
[36] |
Rose NF, Marx PA, Luckay A, et al. (2001) An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106: 539–549. doi: 10.1016/S0092-8674(01)00482-2
![]() |
[37] |
Milligan ID, Gibani MM, Sewell R, et al. (2016) Safety and immunogenicity of novel adenovirus type 26–and modified vaccinia ankara–vectored ebola vaccines: a randomized clinical trial. Jama 315: 1610–1623. doi: 10.1001/jama.2016.4218
![]() |
[38] | Anywaine Z, Whitworth H, Kaleebu P, et al. (2019) Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania. J Infect Dis 220: 46–56. |
[39] | Mutua G, Anzala O, Luhn K, et al. (2019) Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya. J Infect Dis 220: 57–67. |
[40] | World Health Organization (2019) Ebola Vaccines Decision framework. Available from: https://www.who.int/blueprint/priority-%20diseases/keyaction/ebola-vaccinecandidates/en/,%20accessed%2007%20May%202019. |
[41] |
Dhillon RS, Srikrishna D, Kelly JD (2018) Deploying RDTs in the DRC Ebola outbreak. Lancet 391: 2499–2500. doi: 10.1016/S0140-6736(18)31315-1
![]() |
[42] |
Fleck F (2009) The Democratic Republic of the Congo: quantifying the crisis. Bull World Health Organ 87: 6–7. doi: 10.2471/BLT.09.020109
![]() |
[43] | Vinck P, Pham PN, Bindu KK, et al. (2019) Institutional trust and misinformation in the response to the 2018–19 Ebola outbreak in North Kivu, DR Congo: a population-based survey. Lancet Infect Dis19: 529–536. |
[44] |
Caron A, Bourgarel M, Cappelle J, et al. (2018) Ebola Virus Maintenance: If Not (Only) Bats, What Else? Viruses 10: 549. doi: 10.3390/v10100549
![]() |
1. | Maria J. O. Miele, Renato T. Souza, Iracema M. Calderon, Francisco E. Feitosa, Débora F. Leite, Edilberto A. Rocha Filho, Janete Vettorazzi, Jussara Mayrink, Matias C. Vieira, Rodolfo C. Pacagnella, José G. Cecatti, Profile of calories and nutrients intake in a Brazilian multicenter study of nulliparous women, 2021, 0020-7292, 10.1002/ijgo.13655 | |
2. | Daniela Fanni, C. Gerosa, V. M. Nurchi, M. Manchia, L. Saba, F. Coghe, G. Crisponi, Y. Gibo, P. Van Eyken, V. Fanos, G. Faa, The Role of Magnesium in Pregnancy and in Fetal Programming of Adult Diseases, 2020, 0163-4984, 10.1007/s12011-020-02513-0 | |
3. | Kemal Hansu, Ismail Gurkan Cikim, Vitamin and mineral levels during pregnancy, 2022, 68, 1806-9282, 1705, 10.1590/1806-9282.20220769 | |
4. | S. V. Orlova, E. A. Nikitina, Possibilities of perinatal nutrition in implementation of fetal programming, 2021, 2078-5631, 14, 10.33667/2078-5631-2021-26-14-20 | |
5. | Rima Irwinda, Peran Kalsium dan Magnesium pada Kehamilan, 2020, 33, 1979-391X, 3, 10.56951/medicinus.v33i1.1 | |
6. | Hossein Rezazadeh, Mohammad Reza Sharifi, Mohmmadreza Sharifi, Nepton Soltani, Magnesium sulfate improves insulin resistance in high fat diet induced diabetic parents and their offspring, 2021, 909, 00142999, 174418, 10.1016/j.ejphar.2021.174418 | |
7. | S. V. Orlova, E. A. Nikitina, N. V. Balashova, S. G. Gribakin, Yu. A. Pigareva, Vitamins and Minerals in Pregnancy Nutrition: Objections Management, 2023, 2949-2807, 29, 10.33667/2078-5631-2023-8-29-35 | |
8. | Е. А. Nikitina, S. V. Orlova, Т. Т. Batysheva, N. V. Balashova, М. V. Alekseeva, L. Yu. Volkova, A. N. Vodolazkaya, E. V. Prokopenko, Fetal programming as a trend in modern medicine: Magnesium deficiency is the focus, 2023, 2949-2807, 8, 10.33667/2078-5631-2023-29-8-14 |
SGA | AGA | |||
(n = 20) | (n = 45) | |||
[Mg2+]i (μmol/L) | 284 ± 33*** | 468 ± 132 | ||
Plasma Mg(mmol/L) | 0.60 ± 0.03 | 0.61 ± 0.02 | ||
Adiponectin(μg/mL) | 11.4 ± 1.8** | 17.1 ± 1.0 | ||
IGF-1(ng/mL) | 14.3 ± 2.1** | 30.3 ± 2.2 | ||
Leptin(pg/mL) | 845 ± 215 | 1,260 ± 137 | ||
Ghrelin(fmol/mL) | 76.8 ± 11.0* | 53.7 ± 5.1 | ||
PAI-1(ng/mL) | 13.20 ± 2.52* | 7.97 ± 0.94 | ||
QUICKI | 0.35 ± 0.02*** | 0.41 ± 0.01 | ||
SGA: small for gestational age, AGA: appropriate for gestational age, [Mg2+]i: intracellular magnesium, PAI-1: plasminogen activator inhibitor-1, QUICKI: Quantitative insulin sensitivity check index. *p < 0.05, **p < 0.005, ***p < 0.0001 (adapted from Reference 39) |
SGA | AGA | |||
(n = 20) | (n = 45) | |||
[Mg2+]i (μmol/L) | 284 ± 33*** | 468 ± 132 | ||
Plasma Mg(mmol/L) | 0.60 ± 0.03 | 0.61 ± 0.02 | ||
Adiponectin(μg/mL) | 11.4 ± 1.8** | 17.1 ± 1.0 | ||
IGF-1(ng/mL) | 14.3 ± 2.1** | 30.3 ± 2.2 | ||
Leptin(pg/mL) | 845 ± 215 | 1,260 ± 137 | ||
Ghrelin(fmol/mL) | 76.8 ± 11.0* | 53.7 ± 5.1 | ||
PAI-1(ng/mL) | 13.20 ± 2.52* | 7.97 ± 0.94 | ||
QUICKI | 0.35 ± 0.02*** | 0.41 ± 0.01 | ||
SGA: small for gestational age, AGA: appropriate for gestational age, [Mg2+]i: intracellular magnesium, PAI-1: plasminogen activator inhibitor-1, QUICKI: Quantitative insulin sensitivity check index. *p < 0.05, **p < 0.005, ***p < 0.0001 (adapted from Reference 39) |